437764-46-0

Upstream product

• 100-39-0 benzyl bromide 
• 6674-22-2 1,8-diazabicyclo[5.4.0]undec-7-ene 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 

Downstream Products

• 474112-94-2 phenylmethyl 4-bromo-2-(phenyloxy)benzoate 
• 437764-45-9 phenylmethyl 4-bromo-2-(butylamino)benzoate 
• 1268842-14-3 benzyl 3-fluoro-2'-hydroxybiphenyl-4-carboxylate 
• 1268840-77-2 (3R)-3-[(4'-{[4-(7-chloro-3,3-dimethyl-2-oxo-3,4-dihydro-1,5-naphthyridin-1(2H)-yl)piperidin-1-yl]carbonyl}-3'-fluorobiphenyl-2-yl)oxy]butanoic acid 
• 1268842-16-5 benzyl 2'-(3-tert-butoxy-2,2-dimethyl-3oxopropoxy)-3-fluorobiphenyl-4-carboxylate 
• 1268842-20-1 tert-butyl 3-{[3'-fluoro-4'-({4-[(3S)-7-fluoro-3-methyl-2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-1-yl]piperidin-1-yl}carbonyl)biphenyl-2-yl]oxy}-2,2-dimethylpropanoate 
• 1268840-73-8 3-{[3'-fluoro-4'-({4-[(3S)-7-fluoro-3-methyl-2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-1-yl]piperidin-1-yl}carbonyl)biphenyl-2-yl]oxy}-2,2-dimethylpropanoic acid 
• 1268842-26-7 2'-{[(1R)-3-{[tert-butyl(diphenyl)silyl]oxy}-1-methylpropyl]oxy}-3-fluorobiphenyl-4-carboxylic acid 
• 1268842-28-9 1-{1-[(2'-{[(1R)-3-{[tert-butyl(diphenyl)silyl]oxy}-1-methylpropyl]oxy}-3-fluorobiphenyl-4-yl)carbonyl]piperidin-4-yl}-7-chloro-3,3-dimethyl-3,4-dihydro-1,5-naphthyridin-2(1H)-one 
• 1268842-24-5 benzyl 2'-{[(1R)-3-{[tert-butyl(diphenyl)silyl]oxy}-1-methylpropyl]oxy}-3-fluorobiphenyl-4-carboxylate 
• 1268842-30-3 7-chloro-1-{1-[(3-fluoro-2'-{[(1R)-3-hydroxy-1-methylpropyl]oxy}biphenyl-4-yl)carbonyl]piperidin-4-yl}-3,3-dimethyl-3,4-dihydro-1,5-naphthyridin-2(1H)-one 
• 1268842-36-9 benzyl 2'-{[(2S)-3-{[text-butyl(diphenyl)silyl]oxy}-2-methylpropyl]oxy}-3-fluorobiphenyl-4-carboxylate 
• 1268843-48-6 1-{1-[(2'-{[(1R)-3-{[tert-butyl(diphenyl)silyl]oxy}-1-methylpropyl]oxy}-3-fluorobiphenyl-4-yl)carbonyl]piperidin-4-yl}-7-ethyl-3,3-dimethyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one 

Relevant academic research and scientific papers

KIF18A INHIBITORS

Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

KIF18A INHIBITORS

Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

3-(BIARYLOXY) PROPIONIC ACID DERIVATIVE

A compound of the general formula (I): [wherein, R1 represents a halogen atom, or the like, R2 represents a hydrogen atom, or the like, R3 and R4, each independently, represent a hydrogen atom, a C1-4

2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists

This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.

Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists

This invention is related to novel di-substituted aminomethyl chroman derivatives which are useful in the treatment of beta-3 receptor-mediated conditions.